Figure 5: Simulation results.

(A-D): We extended our in vitro experiments to 2 days for untreated control (A), 5 μM Maraviroc (B), 7.5 μM Maraviroc (C), and 10 μM Maraviroc (D). Note that dose escalation increases the number of uninfected cells reduces cell fusion, the number of nuclei in fused cells, and overall viral load. (E-F): We simulated a 2-day treatment with an anti-replication drug (e.g., Remdesivir) calibrated to approximately match experimental responses at 2 days (E). Without additional fitting, we then simulated a combination treatment with 5 μM Maraviroc and the same anti-replication treatment (F). Just as in the experiments, the computational model predicts an additional synergistic improvement in cell survival. We plot the impact on viral load for these virtual experiments in (G)